| Project/Area Number |
19K16808
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2019: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | VAP-1 inhibitor / Immunosuppression / H2O2 / CTLs / ICIs / ICBs |
|---|
| Outline of Research at the Start |
The mechanisms of tumor inhibition of MC-38 mouse model by VAP-1 inhibition with specific inhibitor will be identified. We expect that the reduction of ROS due to inhibition of VAP-1 enzymatic function would be the cause to relieve the immunosuppression and will also synergize with the ICBs.
|
| Outline of Final Research Achievements |
Immunotherapy is a promising treatment modality for cancer. In this study we showed that inhibition of vascular adhesion protein 1, partly responsible for generating immunosuppressive microenvironment, can reverse the unfavorable immune-environment and synergize with current approve immunotherapy.
|
| Academic Significance and Societal Importance of the Research Achievements |
This study showed that oxidative tumor microenvironment can generate immunosuppressive element. This immunosuppression can be altered by inhibiting a particular adhesion protein. This information may help to revise patient care for immunotherapy.
|
